Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline

Author(s):  Klemmer Anja, Krämer Irene, Kamin Wolfgang

Issue:  May/Jun 2013 - Volume 17, Number 3
View All Articles in Issue

Page(s):  254-261

Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 1
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 2
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 3
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 4
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 5
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 6
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 7
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Page 8

Download in electronic PDF format for $65

Abstract:  Knowledge of the physicochemical compatibility of admixtures of nebulizable drugs is an important issue. In this article, the results of our recent study dealing with the compatibility of drug admixtures containing budesonide and colistin methanesulfonate (brand name Colistin CF) or budesonide and 5.85% sodium chloride solution are presented, as well as the up-to-date version of our compatibility table. Admixtures were prepared by mixing 2.0 mL Pulmicort either with 3.0 mL Colistin CF or 4.0 mL 5.85% sodium chloride solution. Test solutions were stored for 24 hours at room temperature under ambient light conditions. Physical compatibility was determined by measuring pH and osmolality. Concentrations of budesonide were measured by a high-performance liquid chromatography assay. The antibiotic activity of colistin methanesulfonate was determined in comparison to standard solutions using a microbiological assay. No loss in drug concentration of budesonide and no change in antibiotic activity of colistin methanesulfonate were detected over a test period of 24 hours. Osmolality remained unchanged in both types of admixtures. In admixtures of budesonide with colistin methanesulfonate, pH increased during the first 4 hours of storage, while in admixtures of budesonide and hypertonic saline pH remained unchanged. No visible changes could be detected. Due to these results admixtures of budesonide and colistin methanesulfonate or 5.85% sodium chloride solution are designated to be compatible, but it is recommended that mixing should take place immediately before administration. Further investigations are needed to determine whether or not drug delivery is affected by mixing the drugs and to ensure simultaneous nebulization is recommendable.

Related Keywords: Anja Klemmer, PharmD, Irene Kramer, PhD, Wolfgang Kamin, MD, drug admixtures, nebulizable agents, aerosolized medications, inhalation solutions, inhalation suspensions, inhalation therapy, physicochemical compatibility, drug stability, budesonide, glucocorticoid, corticosteroid, inhaled steroid, colistin methanesulfonate, anti-inflammatory agent, polymixin antibiotic, antimicrobial agent, antibacterial agent, airway infection, bronchoconstriction, cough, airway inflammation, bronchodilator, osmolality, pH, drug delivery

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, RESPIRATION/LUNG/BREATHING

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Klemmer Anja
, Krämer Irene, Kamin Wolfgang
May/Jun 2013
Pg. 254-261

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley
, Patel Jalpa
May/Jun 2020
Pg. 242-245

Zinc Content of Commercial Diluents Widely Use in Drug Admixtures Prepared for Intravenous Infusion
Desai Narendra R
, Shah Syed M, Koczone Julianna, Vencl-Joncic Maja, Sisto Christopher, Ludwig Stephen A
Sep/Oct 2007
Pg. 426-432

Intravenous Admixture Preparation Considerations, Part 9-B: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
May/Jun 2021
Pg. 222-229

A Review of Parenteral Admixtures Requiring Select Containers and Administration Sets
Rice Stephen P
Mar/Apr 2002
Pg. 120-122

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Drug Compatibility and Stability in Dextrose vs Saline
Newton David W
May/Jun 2011
Pg. 190-192

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
Jan/Feb 2020
Pg. 44-50

Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139

Microwave Freeze-thaw Technique for Injectable Drugs: A Review Updated from 1980 to 2021
Hecq Jean-Daniel
, Soumoy Laura, Closset Mélanie, Colsoul Marie-Lise, Jamart Jacques, Galanti Laurence
Nov/Dec 2021
Pg. 446-462

Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration
Lu Juan
, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T
Jan/Feb 2021
Pg. 52-61

Intravenous Admixture Preparation Considerations, Part 1: Overview of Series on Personnel Selection for Intravenous Admixture Compounding
Allen Loyd V Jr
Nov/Dec 2019
Pg. 478-482

Does Your Drug Expertise Include Clinical Pharmaceutics?
Newton David W
May/Jun 2016
Pg. 202-206

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Intravenous Admixture Preparation Considerations, Part 8: Ready-to-Use Preparations
Allen Loyd V Jr
Jan/Feb 2021
Pg. 31-38

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Compatibility of Micafungin Injection with Other Drugs During Simulated Y-Site Co-administration
Trusley Craig
, Kupiec Thomas C, Trissel Lawrence A
May/Jun 2006
Pg. 230-233

Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie
, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
May/Jun 2022
Pg. 248-254